Teprotumumab for thyroid eye disease: Real world study of patient adherence
February 28, 2022
Dr. Raymond Douglas discusses the real-world adherence to teprotumumab as a treatment for thyroid eye disease.
© 2022 MJH Life Sciences™ and Ophthalmology Times. All rights reserved.
AAO
Tips for better contract negotiations for young ophthalmologists
March 14, 2022
Lisa Nijm, MD, advises young ophthalmologists on how to find common ground with their preferred practice and find solutions in the negotiation process that will help both parties flourish.
Anti-VEGF therapy reduces vision loss, slows progression in severe NPDR
February 24, 2022
Dr. Quan Dong Nguyen reviews a Monte Carlo simulation that showed evidence that treating severe NPDR with anti-VEGF therapy garners positive results.
Baseline factors and how they affect DME resolution
February 14, 2022
Dr. Katherine Talcott discusses baseline factors—CST thickness, hemoglobin A1C, and baseline vision—and their effects on DME resolution.
Dexamethasone inserts after cataract surgery saves time in patient counseling, surgical planning
February 03, 2022
Lisa Nijm, MD, discusses how utilizing a dexamethasone intracanalicular insert after cataract surgery saves time for practices.
Four pearls for corneal collagen cross-linking
February 03, 2022
Preeya Gupta, MD, walks through her four pearls for successful corneal collagen cross-linking, including handling patient expectations, managing the epithelial cells and preventing infectious keratitis.
Ophthalmic bevacizumab deemed effective for treatment of wet macular degeneration in NORSE TWO
January 31, 2022
Firas Rahhal, MD, discusses Outlook Therapeutics’ Phase 3 pivotal NORSE TWO trial for ONS-5010.
Exploring ancillary testing orders by retinal specialists according to the IRIS registry
January 06, 2022
Ted Leng, MD, discusses his IRIS Registry analysis presentation regarding variations in vitreoretinal physician utilization of ancillary testing.
IRIDEX consensus paper investigates best practices for MicroPulse transscleral therapy for glaucoma
January 03, 2022
Robert J. Noecker, MD, MBA, discusses the IRIDEX consensus paper regarding MicroPulse transscleral therapy for glaucoma at AAO 2021.
ARTEMIS study results point to successful IOP lowering with bimatoprost implant
December 30, 2021
At AAO, AbbVie presented results from the ARTEMIS study, showcasing IOP lowering that extends beyond the original 20-month timeframe.